F. Nimmerjahn and J. V. Ravetch, Antibody-mediated modulation of immune responses, Immunol Rev, vol.236, pp.265-75, 2010.

F. Nimmerjahn and J. V. Ravetch, Fc? receptors as regulators of immune responses, Nat Rev Immunol, vol.8, pp.34-47, 2008.

K. Smith and M. R. Clatworthy, Fc?RIIB in autoimmunity and infection: evolutionary and therapeutic implications, Nat Rev Immunol, vol.10, pp.328-371, 2010.

P. J. Leibson, The regulation of lymphocyte activation by inhibitory receptors, Curr Opin Immunol, vol.16, pp.328-364, 2004.

P. Bruhns and F. Jönsson, Mouse and human FcR effector functions, Immunol Rev, vol.268, pp.25-51, 2015.
URL : https://hal.archives-ouvertes.fr/pasteur-01281740

A. Pincetic, S. Bournazos, D. J. Dilillo, J. Maamary, T. T. Wang et al., Type I and type II Fc receptors regulate innate and adaptive immunity, Nat Immunol, vol.15, pp.707-723, 2014.

J. E. Bakema and M. Van-egmond, Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer, Fc Receptors Current Topics in Microbiology and Immunology, vol.382, pp.373-92, 2014.

E. Hatjiharissi, L. Xu, D. D. Santos, Z. R. Hunter, B. T. Ciccarelli et al., Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism, Blood, vol.110, pp.2561-2565, 2007.

L. Ziegler-heitbrock, Blood monocytes and their subsets: established features and open questions, Front Immunol, vol.6, p.423, 2015.

W. H. Yeap, K. L. Wong, N. Shimasaki, E. Teo, J. Quek et al., CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes, Sci Rep, vol.6, p.34310, 2016.

M. J. Smyth, E. Cretney, J. M. Kelly, J. A. Westwood, S. Street et al., Activation of NK cell cytotoxicity, Mol Immunol, vol.42, pp.501-511, 2005.

P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, pp.5640-5649, 2012.

G. J. Weiner, Building better monoclonal antibody-based therapeutics, Nat Rev Cancer, vol.15, pp.361-70, 2015.

P. Bruhns, B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez et al., Specificity and affinity of human Fc? receptors and their polymorphic variants for human IgG subclasses, Blood, vol.113, pp.3716-3741, 2009.
URL : https://hal.archives-ouvertes.fr/pasteur-00363931

W. Weng and R. Levy, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J Clin Oncol Off J Am Soc Clin Oncol, vol.21, pp.3940-3947, 2003.

D. Liu, Y. Tian, D. Sun, H. Sun, Y. Jin et al., The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis, Ann Hematol, vol.95, pp.1483-90, 2016.

P. G. Gavin, N. Song, S. R. Kim, C. Lipchik, N. L. Johnson et al., Association of polymorphisms in FCGR2A and FCGR3A with degree of trastuzumab benefit in the adjuvant treatment of ERBB2/HER2-positive breast cancer: analysis of the NSABP B-31 trial, JAMA Oncol, vol.3, pp.335-376, 2017.

P. Umaña, J. Jean-mairet, R. Moudry, H. Amstutz, and J. E. Bailey, Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity, Nat Biotechnol, vol.17, pp.176-80, 1999.

G. A. Lazar, W. Dang, S. Karki, O. Vafa, J. S. Peng et al., Engineered antibody Fc variants with enhanced effector function, Proc Natl Acad Sci, vol.103, pp.4005-4015, 2006.

Z. Liu, K. Gunasekaran, W. Wang, V. Razinkov, L. Sekirov et al., Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies, J Biol Chem, vol.289, pp.3571-90, 2014.

R. Niwa and M. Satoh, The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology, J Pharm Sci, vol.104, pp.930-971, 2015.

R. Marcus, A. Davies, K. Ando, W. Klapper, S. Opat et al., Obinutuzumab for the first-line treatment of follicular lymphoma, N Engl J Med, vol.377, pp.1331-1375, 2017.

C. Capuano, C. Pighi, R. Molfetta, R. Paolini, S. Battella et al., Obinutuzumab-mediated high-affinity ligation of Fc?RIIIA/CD16 primes NK cells for IFN? production, Oncoimmunology, vol.6, p.1290037, 2017.

S. Dall'ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat et al., Rituximab-dependent cytotoxicity by natural killer cells influence of FCGR3A polymorphism on the concentration-effect relationship, Cancer Res, vol.64, pp.4664-4673, 2004.

N. Gül, L. Babes, K. Siegmund, R. Korthouwer, M. Bögels et al., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy, J Clin Invest, vol.124, pp.812-835, 2014.

E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. Van-rooijen et al., Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30, Blood, vol.110, pp.4370-4372, 2007.

E. Oflazoglu, I. J. Stone, L. Brown, K. A. Gordon, N. Van-rooijen et al., Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40, Br J Cancer, vol.100, pp.113-120, 2009.

M. Horikawa, V. Minard-colin, T. Matsushita, and T. F. Tedder, Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice, J Clin Invest, vol.121, pp.4268-80, 2011.

V. Minard-colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro et al., Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV, Blood, vol.112, pp.1205-1218, 2008.

L. N. Dahal, L. Dou, K. Hussain, R. Liu, A. Earley et al., STING activation reverses lymphoma-mediated resistance to antibody immunotherapy, Cancer Res, vol.77, pp.3619-3650, 2017.

S. Q. Nagelkerke, C. W. Bruggeman, J. Den-haan, E. Mul, T. K. Van-den-berg et al., Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-? receptors, Blood Adv, vol.2, pp.941-53, 2018.

F. O. Martinez, A. Sica, A. Mantovani, and M. Locati, Macrophage activation and polarization, Front Biosci J Virtual Libr, vol.13, pp.453-61, 2008.

J. Golay, F. Da-roit, L. Bologna, C. Ferrara, J. H. Leusen et al., Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab, Blood, vol.122, pp.3482-91, 2013.

S. Herter, M. C. Birk, C. Klein, C. Gerdes, P. Umana et al., Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity, J Immunol, vol.192, pp.2252-60, 2014.

M. Guilliams, P. Bruhns, Y. Saeys, H. Hammad, and B. N. Lambrecht, The function of Fc? receptors in dendritic cells and macrophages, Nat Rev Immunol, vol.14, pp.94-108, 2014.

S. T. Jung, W. Kelton, T. H. Kang, D. Ng, J. T. Andersen et al., Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high Fc?RIIa affinity and selectivity, ACS Chem Biol, vol.8, pp.368-75, 2012.

J. O. Richards, S. Karki, G. A. Lazar, H. Chen, W. Dang et al., Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells, Mol Cancer Ther, vol.7, pp.2517-2544, 2008.

B. Ruffell, A. Au, H. S. Rugo, L. J. Esserman, E. S. Hwang et al., Leukocyte composition of human breast cancer, Proc Natl Acad Sci, vol.109, pp.2796-801, 2012.

S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie et al., Aglycosylated IgG variants expressed in bacteria that selectively bind Fc?RI potentiate tumor cell killing by monocyte-dendritic cells, Proc Natl Acad Sci, vol.107, pp.604-613, 2010.

C. Lee, R. G. Yan, W. Watanabe, M. Charab, W. Todorova et al., IgG Fc domains that bind C1q but not effector Fc? receptors delineate the importance of complement-mediated effector functions, Nat Immunol, vol.18, pp.889-98, 2017.

R. Jefferis, Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action, Trends Pharmacol Sci, vol.30, pp.356-62, 2009.

S. L. Sazinsky, R. G. Ott, N. W. Silver, B. Tidor, J. V. Ravetch et al., Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors, Proc Natl Acad Sci, vol.105, pp.20167-72, 2008.

L. C. Simmons, D. Reilly, L. Klimowski, T. S. Raju, G. Meng et al., Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies, J Immunol Methods, vol.263, pp.133-180, 2002.

M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, and G. Georgiou, Revisiting the role of glycosylation in the structure of human IgG Fc, ACS Chem Biol, vol.7, pp.1596-602, 2012.

D. A. Mancardi, B. Iannascoli, S. Hoos, P. England, M. Daëron et al., FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation, J Clin Invest, vol.118, pp.3738-50, 2008.
URL : https://hal.archives-ouvertes.fr/pasteur-00363913

A. K. Erbe, W. Wang, M. Gallenberger, J. A. Hank, and P. M. Sondel, Genotyping single nucleotide polymorphisms (SNPs) and copy number variability (CNV) of the FCGRs (FCGR3A and FCGR2C) expressed on NK cells, Methods Mol Biol Clifton NJ, vol.1441, pp.43-56, 2016.

J. R. Dobosy, S. D. Rose, K. R. Beltz, S. M. Rupp, K. M. Powers et al.,

, RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers, BMC Biotechnol, 2011.

W. Kelton, N. Mehta, W. Charab, J. Lee, C. Lee et al., IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions, Chem Biol, vol.21, pp.1603-1612, 2014.

E. A. Laborde, S. Vanzulli, M. Beigier-bompadre, M. A. Isturiz, R. A. Ruggiero et al., Immune complexes inhibit differentiation, maturation, and function of human monocyte-derived dendritic cells, J Immunol, vol.179, pp.673-81, 2007.

E. I. Choi, R. Wang, L. Peterson, N. L. Letvin, and K. A. Reimann, Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques, Immunology, vol.124, pp.215-237, 2008.

A. Tamm and R. E. Schmidt, The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for ligand binding, J Immunol, vol.157, pp.1576-81, 1996.

A. Lux, X. Yu, C. N. Scanlan, and F. Nimmerjahn, Impact of immune complex size and glycosylation on IgG binding to human Fc?Rs, J Immunol, vol.190, pp.4315-4338, 2013.

C. Gillis, A. Gouel-chéron, F. Jönsson, and P. Bruhns, Contribution of human Fc?Rs to disease with evidence from human polymorphisms and transgenic animal studies, Front Immunol, vol.5, p.254, 2014.

K. R. Patel, J. T. Roberts, G. P. Subedi, and A. W. Barb, Restricted processing of CD16a/Fc ? receptor IIIa N-glycans from primary human NK cells impacts structure and function, J Biol Chem, vol.293, pp.3477-89, 2018.

X. Wang, M. Mathieu, and R. J. Brezski, IgG Fc engineering to modulate antibody effector functions, Protein Cell, vol.9, pp.63-73, 2018.

A. Zeck, G. Pohlentz, T. Schlothauer, J. Peter-katalini?, and J. T. Regula, Cell typespecific and site directed N-glycosylation pattern of Fc?RIIIa, J Proteome Res, vol.10, pp.3031-3040, 2011.

J. M. Hayes, A. Frostell, R. Karlsson, S. Müller, S. M. Martín et al., Identification of Fc gamma receptor glycoforms that produce differential binding kinetics for rituximab, Mol Cell Proteomics, vol.16, pp.1770-88, 2017.

R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-449, 2000.

K. Santegoets, M. H. Wenink, W. B. Van-den-berg, and T. Radstake, Fc gamma receptor IIb on GM-CSF macrophages controls immune complex mediated inhibition of inflammatory signals, PLoS ONE, vol.9, p.110966, 2014.

S. Q. Nagelkerke, G. Dekkers, I. Kustiawan, F. S. Van-de-bovenkamp, J. Geissler et al., Inhibition of Fc?R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc?RIIb in human macrophages, Blood, vol.124, pp.3709-3727, 2014.

A. P. Trembath and M. A. Markiewicz, More than decoration: roles for natural killer group 2 member D ligand expression by immune cells, Front Immunol, vol.9, p.231, 2018.